A method and device for detecting sample confusion during library construction

The SNP sites of high-throughput sequencing intermediate products were detected by nucleic acid mass spectrometry, and the confusion link of the sample was accurately determined during the library construction process, solving the problem of difficulty in accurately positioning the sample confusion and achieving efficient and low-cost sample detection.

CN113151428BActive Publication Date: 2024-11-05SHANGHAI BIOTECAN PHARMA +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110440968.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-04-23
Publication Date
2024-11-05
Estimated Expiration
2041-04-23

AI Technical Summary

Technical Problem

During high-throughput sequencing, sample confusion is difficult to accurately locate, existing methods cannot determine the specific confusion links of samples in the library construction process, and relying on internal standards increases cost and operational complexity.

Method used

The SNP sites of intermediate products during library construction were detected by nucleic acid mass spectrometry, and the SNP mass spectrometry results of different intermediate products were compared, and the sample confusion link was judged. Specific SNP sites were used to distinguish individuals and determine the confusion link, which reduced sequencing costs.

Benefits of technology

Accurately determine the confusion of samples during the library construction process, reduce sequencing costs, avoid the use of internal standards, and improve the accuracy and efficiency of detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113151428B_ABST
    Figure CN113151428B_ABST
Patent Text Reader

Abstract

The present invention provides a method and device for detecting sample confusion during library construction, the method comprising: using nucleic acid mass spectrometry to detect the SNP sites of intermediate products of samples during library construction, comparing the nucleic acid mass spectrometry results of SNP sites of different intermediate products, and judging the occurrence of sample confusion. Based on the sample SNP site information, the present invention uses nucleic acid mass spectrometry technology to detect the SNP sites of intermediate products during library construction, and compares the SNP detection results of a series of intermediate products, thereby achieving the effect of accurately and low-costly judging the occurrence of sample confusion.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of high-throughput sequencing and relates to a method and device for detecting sample confusion in a library construction process. Background Art

[0002] Next Generation Sequencing (NGS), also known as Next Generating Sequencing, is characterized by high-throughput sequencing of DNA molecules and short sequencing read length. Through integrated detection of multiple genes and multiple sites, gene sites closely related to tumors can be detected at one time. Library construction is one of the most important links in the second generation sequencing. The classic library construction method is to fragment the extracted genomic nucleic acid, and then use probes to capture the target fragments after end repair, adapter ligation, and pre-library amplification for sequencing.

[0003] Mass spectrometry is a powerful comprehensive technology platform with high throughput and high sensitivity. In addition to protein and peptide detection, microbial identification, and glycosylation detection, it can also perform SNP mutation, methylation, and CNV analysis of genes. A major advantage of nucleic acid mass spectrometry is that its spectrum detection peaks show the four bases A, G, T, and C, and the data is accurate and easy to identify.

[0004] Single nucleotide polymorphism (SNP) mainly refers to DNA sequence polymorphism caused by single nucleotide variation at the genome level. SNP is a dimorphic marker, generally caused by the conversion or transversion of a single base, and is widely present in the human genome. On average, there is one SNP site in every 300 base pairs, and SNPs exist in coding regions, non-coding regions, and intergenic regions.

[0005] In the actual operation of high-throughput sequencing, the operator's negligence may lead to confusion of nucleic acid samples, resulting in mismatched sample analysis results or mutations that are inconsistent with the clinical diagnosis. For uncertain results in second-generation sequencing, qPCR, mass spectrometry and other methods are mainly used for verification. However, these methods can only reflect whether there are mutations in the verified samples, and cannot determine whether the samples are confused during the library construction process. At present, the method for detecting cross-sample contamination of nucleic acids is to add SNP primers or internal standards during the library construction process, and use bioinformatics methods to determine whether there is cross-sample contamination of nucleic acids after sequencing is completed.

[0006] CN109686404A discloses a method and device for detecting sample confusion, which includes the following steps: S1, obtaining sequence information of the target gene of the sample to be detected and its control sample; and S2, analyzing the sequence information, screening out the germline site variation information, and determining whether the sample to be detected is in a confused state by calculating the specific type of mutation ratio. This technical solution determines whether the sample is confused based on sequencing data. Since reference products can be saved, costs are saved, and it has the characteristics of high sensitivity and high specificity. However, this method needs to ensure that the primers or reference products are not contaminated, otherwise the results may be wrong. In addition, the additional primers or reference products increase the time cost and sequencing cost of the operation, and it is impossible to determine at which step in the library construction process the sample confusion occurs. Summary of the invention

[0007] In view of the deficiencies in the prior art and actual needs, the present invention provides a method and device for detecting sample confusion in the library construction process. The method performs nucleic acid mass spectrometry detection on the intermediate products in the library construction process based on the sample SNP site information, and makes a judgment on the link where sample confusion occurs according to the nucleic acid mass spectrometry detection results.

[0008] To achieve this object, the present invention adopts the following technical solutions:

[0009] In a first aspect, the present invention provides a method for detecting sample confusion during library construction, the method comprising:

[0010] Nucleic acid mass spectrometry is used to detect the SNP sites of the intermediate products of the samples during the library construction process, and the nucleic acid mass spectrometry results of the SNP sites of different intermediate products are compared to determine the step where the sample confusion occurs.

[0011] In the present invention, based on the SNP site information of the sample, the nucleic acid mass spectrometry technology is used to detect the SNP sites of the intermediate products in the library construction process, and the SNP detection results of a series of intermediate products are compared. In theory, the genetic information of samples in different states or the same sample in different links is the same. If the samples are confused during the library construction process, the erroneous links and the samples that may be confused can be prompted according to the changes in genetic information. The method does not rely on internal standards, the sequencing cost is significantly reduced, and the link where the sample confusion occurs can be accurately determined.

[0012] Preferably, the intermediate product comprises any one of nucleic acid extraction stock solution, nucleic acid fragmentation product, adapter ligation product, amplification library or probe capture library, or a combination of at least two thereof.

[0013] Preferably, the SNP sites include any one of rs2032582, rs2072671, rs4244285, rs11572080, rs1057910, rs55951658, rs67376798, rs3918290, rs1801159, rs1801265, rs11615, rs13181, rs1695, rs1045642, rs4880, rs1131341, rs9937, rs1042858, rs1800460, rs1142345, rs4148323, rs25487 or rs1799782, or a combination of at least two of them. These SNP sites can not only distinguish different individuals, but also cover the detection gene range of different cancer types, and are suitable for sample confusion detection of the final library captured by hybridization.

[0014] In the present invention, the SNP sites selected by the device have high specificity, can screen sites with population differences, and are consistent with the chemotherapy drug sensitivity sites detected by conventional second-generation sequencing. By combining these sites, the purpose of distinguishing different individuals can be achieved.

[0015] Preferably, the PCR primers for rs2032582 include the nucleic acid sequences shown in SEQ ID NOs: 1 to 2, and the extension primers include the nucleic acid sequence shown in SEQ ID NO: 3;

[0016] SEQ ID NO: 1: ACGTTGGATGTGCAATAGCAGGAGTTGTTG;

[0017] SEQ ID NO:2: ACGTTGGATGCATATTTAGTTTGACTCACC;

[0018] SEQ ID NO: 3: TATTGTAGTTTGACTCACCTTCCCAG.

[0019] Preferably, the PCR primers for rs2072671 include the nucleic acid sequences shown in SEQ ID NOs: 4 to 5, and the extension primers include the nucleic acid sequence shown in SEQ ID NO: 6;

[0020] SEQ ID NO: 4: ACGTTGGATGACAGGAAAGTGACTGTAGGG;

[0021] SEQ ID NO: 5: ACGTTGGATGCTGAAGCCTGAGTGTGTCCA;

[0022] SEQ ID NO:6:TCCCAGGAGGCCAAG.

[0023] Preferably, the PCR primers for rs4244285 include the nucleic acid sequences shown in SEQ ID NOs:7-8, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:9;

[0024] SEQ ID NO:7: ACGTTGGATGGCAATAATTTTCCCACTATC;

[0025] SEQ ID NO:8: ACGTTGGATGTCCATCGATTCTTGGTGTTC;

[0026] SEQ ID NO:9: GTTAAGTAATTTGTTATGGGTTCC.

[0027] Preferably, the PCR primers for rs11572080 include the nucleic acid sequences shown in SEQ ID NOs: 10 to 11, and the extension primers include the nucleic acid sequence shown in SEQ ID NO: 12;

[0028] SEQ ID NO: 10: ACGTTGGATGTTTCCTCCTCACAACCTTGC;

[0029] SEQ ID NO: 11: ACGTTGGATGCAGTGAGCTTCCTCTTGAAC;

[0030] SEQ ID NO: 12: ACGGTCCTCAATGCTC.

[0031] Preferably, the PCR primers for rs1057910 include the nucleic acid sequences shown in SEQ ID NOs: 13 to 14, and the extension primers include the nucleic acid sequence shown in SEQ ID NO: 15;

[0032] SEQ ID NO: 13: ACGTTGGATGTGTCACAGGTCACTGCATGG;

[0033] SEQ ID NO: 14: ACGTTGGATGATGCAAGACAGGAGCCACAT;

[0034] SEQ ID NO: 15: ACGAGGTCCAGAGATAC.

[0035] Preferably, the PCR primers for rs55951658 include the nucleic acid sequences shown in SEQ ID NOs: 16 to 17, and the extension primers include the nucleic acid sequence shown in SEQ ID NO: 18;

[0036] SEQ ID NO: 16: ACGTTGGATGCAAATTCAGTGGACTACCCC;

[0037] SEQ ID NO: 17: ACGTTGGATGACTCTAGCCTTTTGGTCCAG;

[0038] SEQ ID NO: 18: GGGATTTATGAAAAGTGCC.

[0039] Preferably, the PCR primers for rs67376798 include the nucleic acid sequences shown in SEQ ID NOs: 19 to 20, and the extension primers include the nucleic acid sequence shown in SEQ ID NO: 21;

[0040] SEQ ID NO: 19: ACGTTGGATGCTTACCTGGTAGCCAGAATC;

[0041] SEQ ID NO:20: ACGTTGGATGGCAACGTAGAGCAAGTTGTG;

[0042] SEQ ID NO:21: AAGTTTGTGGCTATGATTG.

[0043] Preferably, the PCR primers for rs3918290 include the nucleic acid sequences shown in SEQ ID NOs: 22 to 23, and the extension primers include the nucleic acid sequence shown in SEQ ID NO: 24;

[0044] SEQ ID NO: 22: ACGTTGGATGTCACTGAACTAAAGGCTGAC;

[0045] SEQ ID NO: 23: ACGTTGGAATGAACATTCACCAACTTATGCC;

[0046] SEQ ID NO:24: TTGTTTTAGATGTTAAATCACACTTA.

[0047] Preferably, the PCR primers for rs1801159 include the nucleic acid sequences shown in SEQ ID NOs: 25 to 26, and the extension primers include the nucleic acid sequence shown in SEQ ID NO: 27;

[0048] SEQ ID NO: 25: ACGTTGGATGTGCGCTAGCAAGACCAAAAG;

[0049] SEQ ID NO: 26: ACGTTGGATGCTCCTATTGATCTGGTGGAC;

[0050] SEQ ID NO:27:TCCCTGGCCGGATTGAAGTTT.

[0051] Preferably, the PCR primers for rs1801265 include the nucleic acid sequences shown in SEQ ID NOs: 28 to 29, and the extension primers include the nucleic acid sequence shown in SEQ ID NO: 30;

[0052] SEQ ID NO: 28: ACGTTGGATGGTCTAATTTCTTGGCCGAAG;

[0053] SEQ ID NO: 29: ACGTTGGATGATCCTGGCTTTAAATCCTCG;

[0054] SEQ ID NO:30: TGACACAAACTCATGCAACTCTG.

[0055] Preferably, the PCR primers for rs11615 include the nucleic acid sequences shown in SEQ ID NOs:31 to 32, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:33;

[0056] SEQ ID NO: 31: ACGTTGGATGCAGAGCTCACCTGAGGAACA;

[0057] SEQ ID NO: 32: ACGTTGGATGGGCAATCCCGTACTGAAGTT;

[0058] SEQ ID NO: 33: GGGAAGTACTGAAGTTCGTGCGCAA.

[0059] Preferably, the PCR primers for rs13181 include the nucleic acid sequences shown in SEQ ID NOs: 34 to 35, and the extension primers include the nucleic acid sequence shown in SEQ ID NO: 36;

[0060] SEQ ID NO: 34: ACGTTGGATGAGCAGCTAGAATCAGAGGAG;

[0061] SEQ ID NO: 35: ACGTTGGATGCACCAGGAACCGTTTATGGC;

[0062] SEQ ID NO: 36: GAGCAATCTGCTCTTATCCTCT.

[0063] Preferably, the rs1695 PCR primers include the nucleic acid sequences shown in SEQ ID NOs: 37 to 38, and the extension primers include the nucleic acid sequence shown in SEQ ID NO: 39;

[0064] SEQ ID NO: 37: ACGTTGGATGTGGTGCAGATGCTCACATAG;

[0065] SEQ ID NO: 38: ACGTTGGATGTGGTGGACATGGTGAATGAC;

[0066] SEQ ID NO:39:ACCTCCGCTGCAAATAC.

[0067] Preferably, the PCR primers for rs1045642 include the nucleic acid sequences shown in SEQ ID NOs:40 to 41, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:42;

[0068] SEQ ID NO: 40: ACGTTGGATGTATGGAGACAACAGCCGGGT;

[0069] SEQ ID NO: 41: ACGTTGGATGTAGGCAGTGACTCGATGAAG;

[0070] SEQ ID NO:42: CTTTGCTGCCCTCAC.

[0071] Preferably, the PCR primers for rs4880 include the nucleic acid sequences shown in SEQ ID NOs:43 to 44, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:45;

[0072] SEQ ID NO: 43: ACGTTGGATGTGCTTTCTCGTCTTCAGCAC;

[0073] SEQ ID NO: 44: ACGTTGGATGTTCTGCCTGGAGCCCAGATA;

[0074] SEQ ID NO:45: TTAGCCCAGATACCCCAAA.

[0075] Preferably, the PCR primers for rs1131341 include the nucleic acid sequences shown in SEQ ID NOs:46-47, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:48;

[0076] SEQ ID NO: 46: ACGTTGGATGTTGCTTACACTTACGCTGCC;

[0077] SEQ ID NO: 47: ACGTTGGATGCAGAGCATTCAGAACCATCC;

[0078] SEQ ID NO:48: ACCATCCACCTACCC.

[0079] Preferably, the PCR primers for rs9937 include the nucleic acid sequences shown in SEQ ID NOs: 49 to 50, and the extension primers include the nucleic acid sequence shown in SEQ ID NO: 51;

[0080] SEQ ID NO: 49: ACGTTGGATGCCTTATTTAGAGTGAACTGG;

[0081] SEQ ID NO: 50: ACGTTGGATGTGTAGGGTTTGAAGACTGGG;

[0082] SEQ ID NO:51: CCGAATGGGATGTATTATTTAAGGAC.

[0083] Preferably, the PCR primers for rs1042858 include the nucleic acid sequences shown in SEQ ID NOs: 52 to 53, and the extension primers include the nucleic acid sequence shown in SEQ ID NO: 54;

[0084] SEQ ID NO: 52: ACGTTGGATGTGTAGGGTTTGAAGACTGGG;

[0085] SEQ ID NO: 53: ACGTTGGATGCCTTATTTAGAGTGAACTGG;

[0086] SEQ ID NO:54: GTGAACTGGATTGGATTAGC.

[0087] Preferably, the PCR primers for rs1800460 include the nucleic acid sequences shown in SEQ ID NOs:55 to 56, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:57;

[0088] SEQ ID NO: 55: ACGTTGGATGACTTACCATTTGCGATCACC;

[0089] SEQ ID NO: 56: ACGTTGGATGGTTTTTTCTCTTTCTGGTAGG;

[0090] SEQ ID NO: 57: AATGTGACATGATTTGGGATAGAGGA.

[0091] Preferably, the PCR primers for rs1142345 include the nucleic acid sequences shown in SEQ ID NOs: 58 to 59, and the extension primers include the nucleic acid sequence shown in SEQ ID NO: 60;

[0092] SEQ ID NO: 58: ACGTTGGATGAGAACGACATAAAAGTTGGG;

[0093] SEQ ID NO: 59: ACGTTGGATGCCTCAAAAACATGTCAGTGTG;

[0094] SEQ ID NO:60: TCATTTACTTTTCTGTAAGTAGA.

[0095] Preferably, the PCR primers for rs4148323 include the nucleic acid sequences shown in SEQ ID NOs: 61 to 62, and the extension primers include the nucleic acid sequence shown in SEQ ID NO: 63;

[0096] SEQ ID NO: 61: ACGTTGGATGCTGACGCCTCGTTGTACATC;

[0097] SEQ ID NO: 62: ACGTTGGATGACATCCTCCCTTTGGAATGG;

[0098] SEQ ID NO:63: TCAAGGTGTAAAATGCTC.

[0099] Preferably, the PCR primers for rs25487 include the nucleic acid sequences shown in SEQ ID NOs: 64 to 65, and the extension primers include the nucleic acid sequence shown in SEQ ID NO: 66;

[0100] SEQ ID NO: 64: ACGTTGGATGCAGGATAAGGAGCAGGGTTG;

[0101] SEQ ID NO: 65: ACGTTGGATGATCGTGCGTAAGGAGTGGGT;

[0102] SEQ ID NO:66: GAGCGGCGGCTGCCTCCC.

[0103] Preferably, the PCR primers for rs1799782 include the nucleic acid sequences shown in SEQ ID NOs: 67 to 68, and the extension primers include the nucleic acid sequence shown in SEQ ID NO: 69;

[0104] SEQ ID NO: 67: ACGTTGGATGTAGGTCTCAACCCTACTCAC;

[0105] SEQ ID NO: 68: ACGTTGGATGATGAGAGCGCCAACTCTCTG;

[0106] SEQ ID NO:69: TCGGAGGCCGGGGCCTCTTCTTCAGC.

[0107] In the present invention, the product after PCR amplification will undergo a single base extension reaction after adding a SNP sequence-specific extension primer, and ddNTPs are used to replace dNTPs in the reaction system, and a probe is designed adjacent to the SNP site so that the probe only extends one base at the SNP site and then terminates. Depending on the SNP site, the probe will bind to different ddNTPs, thereby having different molecular weights, and the mass spectrometer can detect this molecular weight difference, thereby achieving the purpose of SNP typing.

[0108] Preferably, the sample comprises nucleic acid from blood, saliva, urine, tissue, oral swab or hair follicles.

[0109] In a second aspect, the present invention provides a device for detecting sample confusion during library construction, the device comprising a library construction module, a nucleic acid mass spectrometry detection module, and an information comparison module;

[0110] The library construction module is used to extract nucleic acid from a sample, and perform fragmentation, adapter ligation, library amplification, and target sequence capture, and collect corresponding intermediate products;

[0111] The nucleic acid mass spectrometry detection module is used to detect the SNP sites of the intermediate product;

[0112] The information comparison module is used to compare the nucleic acid mass spectrometry results of different intermediate SNP sites to determine the step where sample confusion occurs.

[0113] Preferably, the SNP site includes any one of rs2032582, rs2072671, rs4244285, rs11572080, rs1057910, rs55951658, rs67376798, rs3918290, rs1801159, rs1801265, rs11615, rs13181, rs1695, rs1045642, rs4880, rs1131341, rs9937, rs1042858, rs1800460, rs1142345, rs4148323, rs25487 or rs1799782, or a combination of at least two of them.

[0114] Preferably, the PCR primers for rs2032582 include the nucleic acid sequences shown in SEQ ID NOs: 1 to 2, and the extension primers include the nucleic acid sequence shown in SEQ ID NO: 3.

[0115] Preferably, the PCR primers for rs2072671 include the nucleic acid sequences shown in SEQ ID NOs: 4 to 5, and the extension primers include the nucleic acid sequence shown in SEQ ID NO: 6.

[0116] Preferably, the PCR primers for rs4244285 include the nucleic acid sequences shown in SEQ ID NOs:7-8, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:9.

[0117] Preferably, the PCR primers for rs11572080 include the nucleic acid sequences shown in SEQ ID NOs:10-11, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:12.

[0118] Preferably, the PCR primers for rs1057910 include the nucleic acid sequences shown in SEQ ID NOs:13-14, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:15.

[0119] Preferably, the PCR primers for rs55951658 include the nucleic acid sequences shown in SEQ ID NOs:16-17, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:18.

[0120] Preferably, the PCR primers for rs67376798 include the nucleic acid sequences shown in SEQ ID NOs: 19 to 20, and the extension primers include the nucleic acid sequence shown in SEQ ID NO: 21.

[0121] Preferably, the PCR primers for rs3918290 include the nucleic acid sequences shown in SEQ ID NOs: 22 to 23, and the extension primers include the nucleic acid sequence shown in SEQ ID NO: 24.

[0122] Preferably, the PCR primers for rs1801159 include the nucleic acid sequences shown in SEQ ID NOs:25 to 26, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:27.

[0123] Preferably, the PCR primers for rs1801265 include the nucleic acid sequences shown in SEQ ID NOs:28-29, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:30.

[0124] Preferably, the PCR primers for rs11615 include the nucleic acid sequences shown in SEQ ID NOs:31 to 32, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:33.

[0125] Preferably, the PCR primers for rs13181 include the nucleic acid sequences shown in SEQ ID NOs:34 to 35, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:36.

[0126] Preferably, the PCR primers for rs1695 include the nucleic acid sequences shown in SEQ ID NOs:37-38, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:39.

[0127] Preferably, the PCR primers for rs1045642 include the nucleic acid sequences shown in SEQ ID NOs:40 to 41, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:42.

[0128] Preferably, the PCR primers for rs4880 include the nucleic acid sequences shown in SEQ ID NOs:43-44, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:45.

[0129] Preferably, the PCR primers for rs1131341 include the nucleic acid sequences shown in SEQ ID NOs:46-47, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:48.

[0130] Preferably, the PCR primers for rs9937 include the nucleic acid sequences shown in SEQ ID NOs:49 to 50, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:51.

[0131] Preferably, the PCR primers for rs1042858 include the nucleic acid sequences shown in SEQ ID NOs:52-53, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:54.

[0132] Preferably, the PCR primers for rs1800460 include the nucleic acid sequences shown in SEQ ID NOs:55 to 56, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:57.

[0133] Preferably, the PCR primers for rs1142345 include the nucleic acid sequences shown in SEQ ID NOs:58-59, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:60.

[0134] Preferably, the PCR primers for rs4148323 include the nucleic acid sequences shown in SEQ ID NOs:61 to 62, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:63.

[0135] Preferably, the PCR primers for rs25487 include the nucleic acid sequences shown in SEQ ID NOs:64 to 65, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:66.

[0136] Preferably, the PCR primers for rs1799782 include the nucleic acid sequences shown in SEQ ID NOs:67-68, and the extension primers include the nucleic acid sequence shown in SEQ ID NO:69.

[0137] Preferably, the sample comprises any one of blood, saliva, urine, tissue, oral swab or hair follicle, or a combination of at least two thereof.

[0138] In a third aspect, the present invention provides use of the device described in the second aspect in preparing high-throughput sequencing quality control reagents.

[0139] Compared with the prior art, the present invention has the following beneficial effects:

[0140] (1) Based on the SNP site information of the sample, the present invention uses nucleic acid mass spectrometry technology to detect the SNP sites of the intermediate products in the library construction process, and compares the SNP detection results of a series of intermediate products. In theory, the genetic information of samples in different states or the same sample in different links is the same. If the samples are confused during the library construction process, the wrong link and the sample that may be confused can be prompted according to the changes in genetic information;

[0141] (2) The method of the present invention does not rely on internal standards, the sequencing cost is significantly reduced, and the link where sample confusion occurs can be accurately determined. BRIEF DESCRIPTION OF THE DRAWINGS

[0142] Figure 1 Schematic diagram of the principle of the method and device for detecting sample confusion during library construction. DETAILED DESCRIPTION

[0143] To further illustrate the technical means and effects of the present invention, the present invention is further described below in conjunction with the embodiments and drawings. It should be understood that the specific implementation methods described herein are only used to explain the present invention, rather than to limit the present invention.

[0144] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0145] Example 1

[0146] When NGS analysis results show that the genetic information of samples after different treatments is not consistent or the test results are inconsistent with the clinical diagnosis (for example, L858 mutation is detected in colorectal cancer samples), nucleic acid mass spectrometry analysis is performed on sample nucleic acids in different states to obtain information on 23 SNP sites;

[0147] In the case where sample A and sample B do not match, if all SNP sites of sample A are consistent, all SNP sites of sample B are also consistent, but there are inconsistent genetic sites among their 23 SNP sites, then the nucleic acids of the two samples are mixed up during extraction or before extraction;

[0148] If the SNP genetic information of sample A or sample B changes in any intermediate link, the SNP genetic information of sample A and sample B before the link is the same, and the SNP genetic information after the link changes;

[0149] In cases where the gene mutation is inconsistent with the clinical diagnosis, the samples from the same batch that may be confused can be verified. For example, if a colorectal cancer sample C from the same batch of samples is detected with an L858 mutation, it is necessary to prioritize the possibility of confusion with lung cancer samples.

[0150] Schematic diagram of the principle of sample confusion during the construction of the detection library Figure 1 As shown, “=” indicates that the SNP genetic information of the two links is the same, and “≠” indicates that the SNP genetic information of the two links is different.

[0151] Example 2

[0152] According to the information submitted for inspection, sample A and sample B are tissue and blood samples from the same individual, and their NGS results show that the matching rate of A and B is only 65.2%. In this embodiment, the nucleic acid mass spectrometry method is used to perform nucleic acid mass spectrometry analysis on the nucleic acid stock solution product S1, nucleic acid fragmentation product S2, WGS library S3 and the second extracted nucleic acid S1-2 of sample A and sample B to obtain the genetic information of 23 SNP sites, as shown in Table 1.

[0153] Table 1

[0154]

[0155]

[0156] It can be seen that the genetic information of sample A is consistent, and the genetic information of sample B is also consistent, but the genetic information of the two samples at the P18 site is completely different. Through verification, it was found that sample A and sample B came from different individuals, and the confusion between sample A and other samples occurred during the nucleic acid extraction or inspection stage.

[0157] Example 3

[0158] Sample C was clinically diagnosed with colorectal cancer, and its NGS test results showed L858 mutation. The nucleic acid stock solution product S1, nucleic acid fragmentation product S2, and WGS library S3 of sample C and a possibly confused sample D from the same batch were subjected to nucleic acid mass spectrometry analysis to obtain genetic information of 23 SNP sites, as shown in Table 2.

[0159] Table 2

[0160]

[0161]

[0162] It can be seen that the genetic information of sample C changes between S1 and S2. The genetic information of S1 of sample C is the same as the genetic information of S2 and S3 of sample D. The genetic information of S1 of sample D is the same as the genetic information of S2 and S3 of sample C, indicating that samples C and D are confused in the interruption stage.

[0163] The applicant declares that the present invention illustrates the detailed method of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned detailed method, that is, it does not mean that the present invention must rely on the above-mentioned detailed method to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention. SEQUENCE LISTING <110> Shanghai Bioteng Biopharmaceutical Technology Co., Ltd. Shanghai Bioteng Medical Laboratory Co., Ltd. Shanghai Zhangjiang Medical Innovation Institute <120> A method and device for detecting sample confusion during library construction <130> 2021 <160> 69 <170> PatentIn version 3.3 <210> 1 <211> 30 <212> DNA <213> Artificial sequence <400> 1 acgttggatg tgcaatagca ggagttgttg 30 <210> 2 <211> 30 <212> DNA <213> Artificial sequence <400> 2 acgttggatg catatttagtttgactcacc 30 <210> 3 <211> 25 <212> DNA <213> Artificial sequence <400> 3 tatgtagttt gactcacctt cccag 25 <210> 4 <211> 30 <212> DNA <213> Artificial sequence <400> 4 acgttggatg acaggaaagt gactgtaggg 30 <210> 5 <211> 30 <212> DNA <213> Artificial sequence <400> 5 acgttggatg ctgaagcctg agtgtgtcca 30 <210> 6 <211> 15 <212> DNA <213> Artificial sequence <400> 6 tcccaggagg ccaag 15 <210> 7 <211> 30 <212> DNA <213> Artificial sequence <400> 7 acgttggatg gcaataattt tcccactatc 30 <210> 8 <211> 30 <212> DNA <213> Artificial sequence <400> 8 acgttggatg tccatcgatt cttggtgttc 30 <210> 9 <211> twenty four <212> DNA <213> Artificial sequence <400> 9 gttaagtaat ttgttatggg ttcc 24 <210> 10 <211> 30 <212> DNA <213> Artificial sequence <400> 10 acgttggatg tttctccctc acaaccttgc 30 <210> 11 <211> 30 <212> DNA <213> Artificial sequence <400> 11 acgttggatg cagtgagctt cctcttgaac 30 <210> 12 <211> 16 <212> DNA <213> Artificial sequence <400> 12 acggtcctca atgctc 16 <210> 13 <211> 30 <212> DNA <213> Artificial sequence <400> 13 acgttggatg tgtcacaggt cactgcatgg 30 <210> 14 <211> 30 <212> DNA <213> Artificial sequence <400> 14 acgttggatg atgcaagaca ggagccacat 30 <210> 15 <211> 17 <212> DNA <213> Artificial sequence <400> 15 acgaggtcca gagatac 17 <210> 16 <211> 30 <212> DNA <213> Artificial sequence <400> 16 acgttggatg caaattcagt ggactacccc 30 <210> 17 <211> 30 <212> DNA <213> Artificial sequence <400> 17 acgttggatg actctagccttttggtccag 30 <210> 18 <211> 19 <212> DNA <213> Artificial sequence <400> 18 gggatttatg aaaagtgcc 19 <210> 19 <211> 30 <212> DNA <213> Artificial sequence <400> 19 acgttggatg cttacctggt agccagaatc 30 <210> 20 <211> 30 <212> DNA <213> Artificial sequence <400> 20 acgttggatg gcaacgtaga gcaagttgtg 30 <210> twenty one <211> 18 <212> DNA <213> Artificial sequence <400> twenty one aagttgtggc tatgattg 18 <210> twenty two <211> 30 <212> DNA <213> Artificial sequence <400> twenty two acgttggatg tcactgaact aaaggctgac 30 <210> twenty three <211> 30 <212> DNA <213> Artificial sequence <400> twenty three acgttggatg aacattcacc aacttatgcc 30 <210> twenty four <211> 26 <212> DNA <213> Artificial sequence <400> twenty four ttgttttaga tgttaaatca cactta 26 <210> 25 <211> 30 <212> DNA <213> Artificial sequence <400> 25 acgttggatg tgcgctagca agaccaaaag 30 <210> 26 <211> 30 <212> DNA <213> Artificial sequence <400> 26 acgttggatg ctcctattga tctggtggac 30 <210> 27 <211> twenty one <212> DNA <213> Artificial sequence <400> 27 tccctggccg gattgaagtt t 21 <210> 28 <211> 30 <212> DNA <213> Artificial sequence <400> 28 acgttggatg gtctaatttc ttggccgaag 30 <210> 29 <211> 30 <212> DNA <213> Artificial sequence <400> 29 acgttggatg atcctggctt taaatcctcg 30 <210> 30 <211> twenty three <212> DNA <213> Artificial sequence <400> 30 tgacacaaac tcatgcaact ctg 23 <210> 31 <211> 30 <212> DNA <213> Artificial sequence <400> 31 acgttggatg cagagctcac ctgaggaaca 30 <210> 32 <211> 30 <212> DNA <213> Artificial sequence <400> 32 acgttggatg ggcaatcccg tactgaagtt 30 <210> 33 <211> 25 <212> DNA <213> Artificial sequence <400> 33 gggaagtact gaagttcgtg cgcaa 25 <210> 34 <211> 30 <212> DNA <213> Artificial sequence <400> 34 acgttggatg agcagctaga atcagaggag 30 <210> 35 <211> 30 <212> DNA <213> Artificial sequence <400> 35 acgttggatg caccaggaac cgtttatggc 30 <210> 36 <211> twenty one <212> DNA <213> Artificial sequence <400> 36 gagcaatctg ctctatcctc t 21 <210> 37 <211> 30 <212> DNA <213> Artificial sequence <400> 37 acgttggatg tggtgcagat gctcacatag 30 <210> 38 <211> 30 <212> DNA <213> Artificial sequence <400> 38 acgttggatg tggtggacat ggtgaatgac 30 <210> 39 <211> 17 <212> DNA <213> Artificial sequence <400> 39 acctccgctg caaatac 17 <210> 40 <211> 30 <212> DNA <213> Artificial sequence <400> 40 acgttggatg tatggagaca acagccgggt 30 <210> 41 <211> 30 <212> DNA <213> Artificial sequence <400> 41 acgttggatg taggcagtga ctcgatgaag 30 <210> 42 <211> 15 <212> DNA <213> Artificial sequence <400> 42 ctttgctgcc ctcac 15 <210> 43 <211> 30 <212> DNA <213> Artificial sequence <400> 43 acgttggatg tgctttctcg tcttcagcac 30 <210> 44 <211> 30 <212> DNA <213> Artificial sequence <400> 44 acgttggatg ttctgcctgg agcccagata 30 <210> 45 <211> 19 <212> DNA <213> Artificial sequence <400> 45 ttagcccaga taccccaaa 19 <210> 46 <211> 30 <212> DNA <213> Artificial sequence <400> 46 acgttggatg ttgcttacac ttacgctgcc 30 <210> 47 <211> 30 <212> DNA <213> Artificial sequence <400> 47 acgttggatg cagagcattc agaaccatcc 30 <210> 48 <211> 15 <212> DNA <213> Artificial sequence <400> 48 accatccacc taccc 15 <210> 49 <211> 30 <212> DNA <213> Artificial sequence <400> 49 acgttggatg ccttatttag agtgaactgg 30 <210> 50 <211> 30 <212> DNA <213> Artificial sequence <400> 50 acgttggatg tgtagggttt gaagactggg 30 <210> 51 <211> 26 <212> DNA <213> Artificial sequence <400> 51 ccgaatggga tgtattattt aaggac 26 <210> 52 <211> 30 <212> DNA <213> Artificial sequence <400> 52 acgttggatg tgtagggttt gaagactggg 30 <210> 53 <211> 30 <212> DNA <213> Artificial sequence <400> 53 acgttggatg ccttatttag agtgaactgg 30 <210> 54 <211> 20 <212> DNA <213> Artificial sequence <400> 54 gtgaactgga ttggattagc 20 <210> 55 <211> 30 <212> DNA <213> Artificial sequence <400> 55 acgttggatg acttaccatt tgcgatcacc 30 <210> 56 <211> 31 <212> DNA <213> Artificial sequence <400> 56 acgttggatg gttttttctc tttctggtag g 31 <210> 57 <211> 26 <212> DNA <213> Artificial sequence <400> 57 aatgtgacat gatttggggat agagga 26 <210> 58 <211> 30 <212> DNA <213> Artificial sequence <400> 58 acgttggatg agaacgacat aaaagttggg 30 <210> 59 <211> 31 <212> DNA <213> Artificial sequence <400> 59 acgttggatg cctcaaaaac atgtcagtgt g 31 <210> 60 <211> twenty three <212> DNA <213> Artificial sequence <400> 60 tcatttactt ttctgtaagt aga 23 <210> 61 <211> 30 <212> DNA <213> Artificial sequence <400> 61 acgttggatg ctgacgcctc gttgtacatc 30 <210> 62 <211> 30 <212> DNA <213> Artificial sequence <400> 62 acgttggatg acatcctccc tttggaatgg 30 <210> 63 <211> 18 <212> DNA <213> Artificial sequence <400> 63 tcaaggtgta aaatgctc 18 <210> 64 <211> 30 <212> DNA <213> Artificial sequence <400> 64 acgttggatg caggataagg agcagggttg 30 <210> 65 <211> 30 <212> DNA <213> Artificial sequence <400> 65 acgttggatg atcgtgcgta aggagtgggt 30 <210> 66 <211> 20 <212> DNA <213> Artificial sequence <400> 66 gaggcggcgg ctgccctccc 20 <210> 67 <211> 30 <212> DNA <213> Artificial sequence <400> 67 acgttggatg taggtctcaa ccctactcac 30 <210> 68 <211> 30 <212> DNA <213> Artificial sequence <400> 68 acgttggatg atgagagcgc caactctctg 30 <210> 69 <211> 28 <212> DNA <213> Artificial sequence <400> 69 tcggaggccg gggcctctct tcttcagc 28

Claims

1. A method for detecting sample confusion during library construction, characterized in that: The method comprises: The step of detecting the SNP sites of the intermediate products of the samples in the library construction process by nucleic acid mass spectrometry, comparing the nucleic acid mass spectrometry results of the SNP sites of different intermediate products, and determining whether sample confusion occurs; the samples are derived from humans; The intermediate products include nucleic acid extraction stock solution, nucleic acid fragmentation products, adapter ligation products, amplification libraries and probe capture libraries; The SNP sites include rs2032582, rs2072671, rs4244285, rs11572080, rs1057910, rs55951658, rs67376798, rs3918290, rs1801159, rs1801265, rs11615, rs13181, rs1695, rs1045642, rs4880, rs1131341, rs9937, rs1042858, rs1800460, rs1142345, rs4148323, rs25487 and rs1799782; The PCR primers for rs2032582 are the nucleic acid sequences shown in SEQ ID NOs: 1 to 2, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 3; The PCR primers for rs2072671 are the nucleic acid sequences shown in SEQ ID NOs: 4 to 5, and the extension primer is the nucleic acid sequence shown in SEQ ID NO: 6; The PCR primers for rs4244285 are the nucleic acid sequences shown in SEQ ID NOs:7-8, and the extension primers are the nucleic acid sequences shown in SEQ ID NO:9; The PCR primers for rs11572080 are the nucleic acid sequences shown in SEQ ID NOs: 10 to 11, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 12; The rs1057910 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 13-14, and the extension primer is the nucleic acid sequence shown in SEQ ID NO: 15; The PCR primers for rs55951658 are the nucleic acid sequences shown in SEQ ID NOs: 16 to 17, and the extension primer is the nucleic acid sequence shown in SEQ ID NO: 18; The PCR primers for rs67376798 are the nucleic acid sequences shown in SEQ ID NOs: 19 to 20, and the extension primer is the nucleic acid sequence shown in SEQ ID NO: 21; The rs3918290 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 22-23, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 24; The rs1801159 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 25-26, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 27; The rs1801265 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 28-29, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 30; The rs11615 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 31 to 32, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 33; The rs13181 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 34 to 35, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 36; The rs1695 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 37-38, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 39; The PCR primers for rs1045642 are the nucleic acid sequences shown in SEQ ID NOs: 40-41, and the extension primer is the nucleic acid sequence shown in SEQ ID NO: 42; The rs4880 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 43-44, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 45; The rs1131341 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 46-47, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 48; The rs9937 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 49 to 50, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 51; The PCR primers for rs1042858 are the nucleic acid sequences shown in SEQ ID NOs: 52-53, and the extension primer is the nucleic acid sequence shown in SEQ ID NO: 54; The PCR primers for rs1800460 are the nucleic acid sequences shown in SEQ ID NOs: 55 to 56, and the extension primer is the nucleic acid sequence shown in SEQ ID NO: 57; The rs1142345 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 58-59, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 60; The PCR primers for rs4148323 are the nucleic acid sequences shown in SEQ ID NOs: 61 to 62, and the extension primer is the nucleic acid sequence shown in SEQ ID NO: 63; The rs25487 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 64-65, and the extension primer is the nucleic acid sequence shown in SEQ ID NO: 66; The PCR primers for rs1799782 are the nucleic acid sequences shown in SEQ ID NOs: 67-68, and the extension primer is the nucleic acid sequence shown in SEQ ID NO:

69.

2. The method according to claim 1, characterized in that The sample includes nucleic acid from blood, saliva, urine, tissue, oral swab or hair follicles.

3. A device for detecting sample confusion during library construction, characterized in that: The device includes a library construction module, a nucleic acid mass spectrometry detection module and an information comparison module; The library construction module is used to extract nucleic acid from a sample, and perform fragmentation, linker ligation, library amplification, and target sequence capture, and collect corresponding intermediate products; the sample is derived from a human; The nucleic acid mass spectrometry detection module is used to detect the SNP sites of the intermediate product; The information comparison module is used to compare the nucleic acid mass spectrometry results of different intermediate SNP sites to determine the step where sample confusion occurs; The SNP sites include rs2032582, rs2072671, rs4244285, rs11572080, rs1057910, rs55951658, rs67376798, rs3918290, rs1801159, rs1801265, rs11615, rs13181, rs1695, rs1045642, rs4880, rs1131341, rs9937, rs1042858, rs1800460, rs1142345, rs4148323, rs25487 and rs1799782; The PCR primers for rs2032582 are the nucleic acid sequences shown in SEQ ID NOs: 1 to 2, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 3; The PCR primers for rs2072671 are the nucleic acid sequences shown in SEQ ID NOs: 4 to 5, and the extension primer is the nucleic acid sequence shown in SEQ ID NO: 6; The PCR primers for rs4244285 are the nucleic acid sequences shown in SEQ ID NOs:7-8, and the extension primers are the nucleic acid sequences shown in SEQ ID NO:9; The PCR primers for rs11572080 are the nucleic acid sequences shown in SEQ ID NOs: 10 to 11, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 12; The rs1057910 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 13-14, and the extension primer is the nucleic acid sequence shown in SEQ ID NO: 15; The PCR primers for rs55951658 are the nucleic acid sequences shown in SEQ ID NOs: 16 to 17, and the extension primer is the nucleic acid sequence shown in SEQ ID NO: 18; The PCR primers for rs67376798 are the nucleic acid sequences shown in SEQ ID NOs: 19 to 20, and the extension primer is the nucleic acid sequence shown in SEQ ID NO: 21; The rs3918290 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 22-23, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 24; The rs1801159 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 25-26, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 27; The rs1801265 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 28-29, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 30; The rs11615 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 31 to 32, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 33; The rs13181 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 34 to 35, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 36; The rs1695 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 37-38, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 39; The PCR primers for rs1045642 are the nucleic acid sequences shown in SEQ ID NOs: 40-41, and the extension primer is the nucleic acid sequence shown in SEQ ID NO: 42; The rs4880 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 43-44, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 45; The rs1131341 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 46-47, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 48; The rs9937 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 49 to 50, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 51; The PCR primers for rs1042858 are the nucleic acid sequences shown in SEQ ID NOs: 52-53, and the extension primer is the nucleic acid sequence shown in SEQ ID NO: 54; The PCR primers for rs1800460 are the nucleic acid sequences shown in SEQ ID NOs: 55 to 56, and the extension primer is the nucleic acid sequence shown in SEQ ID NO: 57; The rs1142345 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 58-59, and the extension primers are the nucleic acid sequences shown in SEQ ID NO: 60; The PCR primers for rs4148323 are the nucleic acid sequences shown in SEQ ID NOs: 61 to 62, and the extension primer is the nucleic acid sequence shown in SEQ ID NO: 63; The rs25487 PCR primers are the nucleic acid sequences shown in SEQ ID NOs: 64-65, and the extension primer is the nucleic acid sequence shown in SEQ ID NO: 66; The PCR primers for rs1799782 are the nucleic acid sequences shown in SEQ ID NOs: 67-68, and the extension primer is the nucleic acid sequence shown in SEQ ID NO:

69.

4. The device according to claim 3, characterized in that The sample includes any one of blood, saliva, urine, tissue, oral swab or hair follicle, or a combination of at least two of them.